Superkine Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Superkine program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Superkine Program Today - Breaking & Trending Today

Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights

Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Superkine Immunotherapies , Tony Russo , Elizabeth Williams , Superkine Program , Trademark Office , Medicenna Therapeutics Corp , Meeting Of The International Cytokine Interferon Society , Society For Immunotherapy Of Cancer , Oppenheimer Co , Drug Administration , Reports Fiscal Year , Fahar Merchant , United States Patent , American Association , Annual Meeting , International Cytokine , Orphan Drug , Annual Report , Chief Financial Officer , Russo Partners ,

Form 6-K Medicenna Therapeutics For: Jun 22

Form 6-K Medicenna Therapeutics For: Jun 22
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Lillian Siu , David Mooney , Kapil Dhingra , John Sampson , Burkhard Becher , Medicenna Superkine , Peter Lloyd , Elizabeth Williams , Sergio Quezada , Hussein Tawbi , Paul Smith , William Redmond , Martin Bexon , Superkine Immunotherapies , L Bruce Pearce , Paolo Ascierto , Johnh Sampson , Duke University School Of Medicine , Company Nasdaq , Development Advisory Committee , Society For Neuro , Commission File Number , Medicenna Therapeutics Corp , American Association For Cancer Research , Gbm Program ,

Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights

Phase 1/2 ABILITY Study of MDNA11 in patients with advanced solid tumors remains on track for initiation in the third quarter of calendar 2021 ....

United States , United Kingdom , Elizabeth Williams , Superkine Immunotherapies , Mann Muhsin , Human Research Ethics Committee , American Association Of Cancer Research , Medicenna Therapeutics Corp , Gbm Program , Superkine Program , Research Institute Of Texas , Clinical Cancer Research , Medicenna Therapeutics , Fahar Merchant , Recurrent Glioblastoma , Cancer Research , Annual Meeting , Kevin Moulder , Chief Scientific Officer , Chief Medical Officer , Cancer Prevention , Research Institute , United Sates , Empowered Superkines , Orphan Drug , Information For ,

Medicenna Reports Third Quarter Fiscal 2021 Financial Results and Operational Highlights

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Medicenna Reports Third Quarter Fiscal 2021 Financial Results and Operational Highlights
Medicenna Therapeutics Corp.February 12, 2021 GMT
TORONTO and HOUSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) Medicenna Therapeutics Corp. (“Medicenna” or “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended December 31, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted.
“Last quarter we achieved key regulatory milestones across our pipeline that position us for what we expect to be a catalyst rich calendar year,” said Dr. Fahar Merchant, Chairman, President and Chief Executive Officer of Medicenna. “The FDA’s acceptance of our precedent-setting registration trial design for MDNA55 in recurrent glioblastoma we believe has bolste ....

United Kingdom , United States , Elizabeth Williams , David Reardon , Amy Mckee Parexel , Medicenna Or Company , Glioblastoma Drug Development Summit , Drug Administration , Harvard Medical School , Regulatory Agency , Medicenna Therapeutics Corp , Recurrent Glioblastoma Program , John Sampson Duke School Of Medicine , Superkine Program , Fahar Merchant , Chief Executive Officer , John Sampson , Duke School , Ruthie Davi , Amy Mckee , Annual Glioblastoma Drug Development , Scientific Advice Meeting , Investigational Medical Product Dossier , Molecular Targets , Empowered Superkines , Orphan Drug ,